Motley Fool Australia

Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $1.11 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 280.41 million
Earnings per share -0.144
Dividend per share N/A
Year To Date Return 1.32%
Earnings Yield N/A
Franking N/A

Telix Pharmaceuticals Ltd (ASX: TLX) Latest News

Investor riding a rocket blasting off over a share price chart

Why has the Telix (ASX:TXL) share price shot up 5% today?

More »

hand on touch screen lit up by a share price chart moving higher

Why Laybuy, Mesoblast, Sandfire, & Telix shares are charging higher

More »

unstoppable asx share price represented by man in superman cape pointing skyward

Why the Telix (ASX:TLX) share price is up 9% to a new record high today

More »

hand on touch screen lit up by a share price chart moving higher

Why Afterpay, Bega Cheese, Humm, & Telix shares are storming higher

More »

Chalk-drawn rocket shown blasting off into space

Telix (ASX:TLX) share price storms 8% higher to record high on acquisition news

More »

Rising ASX share price represented by investors jumping high in the air

Why these All Ords shares have almost doubled in value this month

More »

Investor riding a rocket blasting off over a share price chart

Why Brickworks, Mesoblast, Qantas, & Telix shares are storming higher

More »

rising medical asx share price represented by FDA approval stamp

Why the Telix (ASX:TLX) share price is surging 8%

More »

About Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Mar 2021 $3.96 $0.13 3.39% 511,280 $3.76 $4.06 $3.76
26 Feb 2021 $3.83 $-0.10 -2.54% 550,545 $3.92 $3.92 $3.71
25 Feb 2021 $3.93 $0.02 0.51% 242,516 $3.91 $3.98 $3.90
24 Feb 2021 $3.91 $-0.09 -2.25% 603,037 $4.00 $4.05 $3.91
23 Feb 2021 $4.00 $-0.10 -2.44% 613,575 $4.07 $4.08 $3.94
22 Feb 2021 $4.10 $-0.03 -0.73% 695,833 $4.12 $4.15 $4.05
19 Feb 2021 $4.13 $0.00 0.00% 523,224 $4.18 $4.22 $4.13
18 Feb 2021 $4.13 $-0.04 -0.96% 254,991 $4.22 $4.22 $4.12
17 Feb 2021 $4.17 $0.02 0.48% 288,552 $4.26 $4.26 $4.07
16 Feb 2021 $4.15 $0.03 0.73% 381,154 $4.15 $4.31 $4.06
15 Feb 2021 $4.12 $-0.03 -0.72% 825,704 $4.24 $4.37 $4.12
12 Feb 2021 $4.15 $0.05 1.22% 342,456 $4.19 $4.23 $4.15
11 Feb 2021 $4.10 $-0.20 -4.65% 467,247 $4.30 $4.35 $4.06
10 Feb 2021 $4.30 $-0.10 -2.27% 337,374 $4.45 $4.49 $4.28
09 Feb 2021 $4.40 $0.03 0.69% 372,990 $4.39 $4.47 $4.31
08 Feb 2021 $4.37 $0.18 4.30% 548,097 $4.20 $4.42 $4.17
05 Feb 2021 $4.19 $0.23 5.81% 527,308 $4.06 $4.36 $4.04
04 Feb 2021 $3.96 $-0.28 -6.60% 431,625 $4.20 $4.24 $3.96
03 Feb 2021 $4.24 $0.12 2.91% 663,650 $4.12 $4.25 $4.02
02 Feb 2021 $4.12 $0.24 6.19% 481,226 $4.02 $4.17 $3.97
01 Feb 2021 $3.88 $-0.05 -1.27% 1,139,766 $3.86 $3.95 $3.66
Show more

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
02 Nov 2020 Oliver Buck Exercise 165 $140,530
02 Nov 2020 Oliver Buck Buy 165 $140,530
12 May 2020 Christian Behrenbruch Issued 200 $294,000


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Harry Kevin McCann Non-Executive Chairman,Non-Executive Director Sep 2017
Ms Jann E Skinner Non-Executive Director Jun 2018
Dr Christian Peter Behrenbruch Chief Executive Officer,Managing Director Jan 2017
Dr Andreas Kluge Executive Director,Chief Medical Officer Jan 2017
Mr Oliver Buck Non-Executive Director Jan 2017
Dr Mark Alexander Nelson Non-Executive Director Sep 2017
Ms Melanie Farris Company Secretary Mar 2017
David Cade Chief Business Officer & Head of Investor Relations
Melanie Farris Company Secretary
Ros Wilson Global Head of Drug Development
Douglas Cubbin Group Chief Financial Officer
Gabriel Liberatore Group Chief Operating Officer
Melanie Farris Group Secretary & Head of Corporate Governance Chief People Officer
Ludovic Wouters President, Telix Europe (Interim)
Shintaro Nishimura President, Telix Japan
Bernard Lambert President, Telix USA
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 32,489,522 12.83%
Elk River Holdings Pty Ltd 24,675,000 9.74%
Gnosis Verwaltungsgesellschaftm B H 24,675,000 9.74%
BNP Paribas Noms Pty Ltd 9,406,521 3.71%
Dale Ltd 7,995,600 3.16%
J P Morgan Nominees Australia Pty Limited 7,515,730 2.97%
The Oncidium Foundation 6,719,898 2.65%
Citicorp Nominees Pty Limited 4,841,331 1.91%
Uv Cap Gmbh & Co Kg 4,700,000 1.86%
UBS Nominees Pty Ltd 4,277,983 1.69%
Jean-Marc Le Doussal 3,901,554 1.54%
BNP Paribas Nominees Pty Ltd 3,845,417 1.52%
HSBC Custody Nominees (Australia) Limited A/C 2 3,425,710 1.35%
Uv-Cap Gmbh & Co 3,075,000 1.21%
National Nominees Limited 2,941,405 1.16%
Remora Capital 2,613,163 1.03%
Ilusa Sprl 2,558,138 1.01%
Yelwac Pty Ltd 2,381,804 0.94%
Cyclotek Pty Ltd 2,350,000 0.93%
Sargon Ct Pty Ltd 2,242,500 0.89%
Man Holdings Pty Ltd 2,238,750 0.88%
Show more